This key finding has shaped the future direction for the drug as Mologen...
Improved clinical efficacy found wanting in Phase III IMPALA trial
This key finding has shaped the future direction for the drug as Mologen AG has confirmed that it will only pursue combination studies.
Redx Pharma to continue studying RXC004 in Phase I/II trial
UK-based biotechnology firm Redx Pharma has received a recommendation from a safety review committee to continue the evaluation of its cancer asset, RXC004, in an ongoing Phase I/II clinical trial.
Study finds majority of cancer drug trials lack racial diversity
A new study in the US has found that less than 8% of oncology clinical trials over the past decade featured participants from the country's major races.
Xpovio (selinexor) for the Treatment of Multiple Myeloma
Xpovio™ (selinexor) is the first nuclear export inhibitor approved in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM) in adult patients.
Lynparza improves survival in Phase III ovarian cancer patients
AstraZeneca and MSD have reported that the Phase III PAOLA-1 study of Lynparza (olaparib) in combination with bevacizumab met the primary endpoint in advanced ovarian cancer patients.
Deciphera reports positive results from INVICTUS study
Deciphera Pharmaceuticals has announced positive findings from the Phase III INVICTUS clinical trial that evaluated ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumours (GIST).
Basilea initiates trial of derazantinib to treat urothelial cancer
Swiss biopharmaceutical firm Basilea Pharmaceutica has launched a clinical trial to assess derazantinib both as a monotherapy and with Roche's atezolizumab to treat urothelial cancer.
Onconova, Mission Bio partner to advance oncology trials using single-cell genomics
Onconova Therapeutics has formed a strategic collaboration to use Mission Bio’s Tapestri platform for targeted single-cell DNA analysis in order to study its novel cancer therapy, rigosertib, through clinical trials.
AstraZeneca reports positive results from trial of Tagrisso
AstraZeneca has reported positive results from the Phase III Flaura trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC).